Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy

Ken Herrmann; Kambiz Rahbar; Matthias Eiber; Richard Sparks; Nicholas Baca; Bernd J. Krause; Michael Lassmann; Walter Jentzen; Jun Tang; Daniela Chicco; Patrick Klein; Lars Blumenstein; Jean-René Basque; Jens Kurth

doi:10.2967/jnumed.123.265448

Research ArticleClinical Investigation

Open Access

Renal and Multiorgan Safety of ¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy

Ken Herrmann, Kambiz Rahbar, Matthias Eiber, Richard Sparks, Nicholas Baca, Bernd J. Krause, Michael Lassmann, Walter Jentzen, Jun Tang, Daniela Chicco, Patrick Klein, Lars Blumenstein, Jean-René Basque and Jens Kurth

Journal of Nuclear Medicine January 2024, 65 (1) 71-78; DOI: https://doi.org/10.2967/jnumed.123.265448

Ken Herrmann

1Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium, University Hospital Essen, Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Kambiz Rahbar

2Department of Nuclear Medicine, University Hospital Münster, Münster, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Matthias Eiber

3Technical University of Munich, Munich, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Richard Sparks

4CDE Dosimetry Services, Knoxville, Tennessee;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Nicholas Baca

4CDE Dosimetry Services, Knoxville, Tennessee;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Bernd J. Krause

5Department of Nuclear Medicine, Rostock University Medical Center, Rostock, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Michael Lassmann

6Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Walter Jentzen

1Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium, University Hospital Essen, Essen, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jun Tang

7Novartis Pharmaceuticals Corporation, East Hanover, New Jersey;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Daniela Chicco

8Advanced Accelerator Applications, a Novartis Company, Turin, Italy;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Patrick Klein

9Novartis Institutes for BioMedical Research, East Hanover, New Jersey;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Lars Blumenstein

10Novartis Institutes for BioMedical Research, Basel, Switzerland; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jean-René Basque

11Novartis Pharma AG, Basel, Switzerland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jens Kurth

5Department of Nuclear Medicine, Rostock University Medical Center, Rostock, Germany;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 65, Issue 1

January 1, 2024

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Renal and Multiorgan Safety of ¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy

Journal of Nuclear Medicine Jan 2024, 65 (1) 71-78; DOI: 10.2967/jnumed.123.265448

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Renal and Multiorgan Safety of ¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy

Journal of Nuclear Medicine Jan 2024, 65 (1) 71-78; DOI: 10.2967/jnumed.123.265448

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

PubMed
Google Scholar

Cited By...

Preclinical Evaluation of 177Lu-rhPSMA-10.1, a Radiopharmaceutical for Prostate Cancer: Biodistribution and Therapeutic Efficacy
Safety, Dosimetry, and Feasibility of [68Ga]Ga-PSMA-R2 as an Imaging Agent in Patients with Biochemical Recurrence or Metastatic Prostate Cancer
Mathematic Modeling of Tumor Growth During [177Lu]Lu-PSMA Therapy: Insights into Treatment Optimization
Challenges with 177Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice
First-Strike Rapid Predictive Dosimetry and Dose Response for 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
Dosimetry of [177Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis

Google Scholar

Keywords

177Lu
prostate-specific membrane antigen
metastatic castration-resistant prostate cancer
radioligand therapy

Main menu

User menu

Search

Renal and Multiorgan Safety of ¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords